NetPeps GLP1-TRZ, or LY3298176, is a unimolecular dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist that is under study for its glycemic control and weight loss benefits .

Tirzepatide is based on the human GIP hormone and has a length of 39 amino acids. It includes a C20 fatty di-acid moiety that provides extended duration and allows for once-weekly dosing in humans .

Following extensive clinical testing, including against comparable treatments, tirzepatide was approved in May 2022 by the United State Food and Drug Administration (USFDA) as a type 2 diabetes (T2D) treatment. It became the first dual GLP-1 and GIP receptor agonist indicated for T2D.

Tirzepatide is now in clinical trials to establish its safety and efficacy as a weight loss treatment in adults with a body mass index (BMI) of 27 or greater, with the initial results suggesting that it provides significant and sustained weight management benefits .

While it is now an approved prescription medication for T2D patients, tirzepatide is also available as a reference material to credentialed professionals wishing to conduct research on this novel GLP-1/GLP agonist.

NetPeps offers products solely for research and development purposes, not for human consumption, medical, or therapeutic applications. Our products should not be misconstrued or substituted as prescription drugs. We do not dispense any prescription medications and are not a pharmacy. The US Food and Drug Administration has not assessed the assertions made on our website. Products are not intended to diagnose, treat, cure, or prevent any medical conditions or diseases.